press_release_id,company_name,category,release_date,ingested_at,title,full_text,source,source_url,parser_version,schema_version,title_clean,full_text_clean
19784d0769cf72a8,Chemometec A/S,unknown,2025-06-18,2025-08-20T21:41:35+00:00,Please confirm your email alert subscriptions for Chemometec A/S,"



























































Thank you for registering.
                                            






You have registered to receive email alerts from 
Chemometec A/S
. Please confirm your registration below. If you did not intend to register for these alerts, simply discard this email. This link will expire in 7 days.
	                                        












Confirm your registration →































Notified, 11 Farnsworth Street, Boston, MA 02210 | 800/990-6397
                    















",gmail,,1,1,Please confirm your email alert subscriptions for Chemometec A/S,"Thank you for registering. You have registered to receive email alerts from Chemometec A/S . Please confirm your registration below. If you did not intend to register for these alerts, simply discard this email. This link will expire in 7 days. Confirm your registration → Notified, 11 Farnsworth Street, Boston, MA 02210 | 800/990-6397"
19784d1055d423e3,Chemometec A/S,unknown,2025-06-18,2025-08-20T21:41:36+00:00,Please confirm your email alert subscriptions for Chemometec A/S,"



























































Thank you for registering.
                                            






You have registered to receive email alerts from 
Chemometec A/S
. Please confirm your registration below. If you did not intend to register for these alerts, simply discard this email. This link will expire in 7 days.
	                                        












Confirm your registration →































Notified, 11 Farnsworth Street, Boston, MA 02210 | 800/990-6397
                    















",gmail,,1,1,Please confirm your email alert subscriptions for Chemometec A/S,"Thank you for registering. You have registered to receive email alerts from Chemometec A/S . Please confirm your registration below. If you did not intend to register for these alerts, simply discard this email. This link will expire in 7 days. Confirm your registration → Notified, 11 Farnsworth Street, Boston, MA 02210 | 800/990-6397"
19784d388e665064,Corem Property Group,unknown,2025-06-18,2025-08-20T21:41:38+00:00,Välkommen som prenumerant,"[*] 
Välkommen som prenumerant hos Corem Property Group!

Från och med nu kommer du att få information från Corem Property Group till denna e-postadress.





För att hantera din prenumerationen, var vänlig klicka på länken nedan (om du inte kan klicka på länken, kopiera länken och klistra in den i webläsaren)

Avsluta prenumeration

",gmail,,1,1,Välkommen som prenumerant,"[*] Välkommen som prenumerant hos Corem Property Group! Från och med nu kommer du att få information från Corem Property Group till denna e-postadress. För att hantera din prenumerationen, var vänlig klicka på länken nedan (om du inte kan klicka på länken, kopiera länken och klistra in den i webläsaren) Avsluta prenumeration"
19788725bfd29835,Dometic Group AB,unknown,2025-06-19,2025-08-20T21:31:18+00:00,Dometic Group AB - Please confirm your subscription,"<div style=""font-family:Arial, Helvetica, Sans-serif; font-size:10pt;"">
	<p>Dear Subscriber,</p>
	<p>Please click <a href=""https://tools.eurolandir.com/tools/SubscriptionCentre2/Home/ConfirmSubscription?sid=RUFBQUFEaWtHR2FOQm9qa2R4T3hPY1AzUjFGNUlpT05uVHVRc0ZHdVMzcW0zV1V6OUx0SWJQVVUra2xoVlJ0bXUyR3hpRFZBNmYzYVBIUmdBWjNxNk14M0d4bUdPQXYvL0hjMGtYdGd2dWtiZDJVRg2&lang=en-GB&companycode=S-DOM"" target=""_blank"">here</a> to confirm your subscription.</p>
	<p>Once you confirm, your subscription will start.</p>
	<br/>
	<br/>
	<hr style=""border: none; border-bottom: 1px solid #E0E0E0;"">
	<div style=""text-align: center;"">
	You are receiving this email because you are in process of subscribing to our Subscription Center. If this wasn’t requested by you, please ignore this email.
	</div>
	<br/>
	<div style=""text-align:center;color:#828282"">
	Supplied © <a href=""http://www.euroland.com"" style=""color:#828282;text-decoration:none"" target=""_blank"">Euroland.com</a>&nbsp;-&nbsp;<a href=""https://tools.eurolandir.com/legal/privacy/"" style=""color:#828282;text-decoration:none"" target=""_blank"">Privacy Policy</a>
	</div>
</div>",gmail,,1,1,Dometic Group AB - Please confirm your subscription,"Dear Subscriber, Please click here to confirm your subscription. Once you confirm, your subscription will start. You are receiving this email because you are in process of subscribing to our Subscription Center. If this wasn’t requested by you, please ignore this email. Supplied © Euroland.com - Privacy Policy"
1981d6a0f5667e31,ALK,unknown,2025-07-18,2025-08-20T16:41:30+00:00,EURneffy® approved as the first needle-free anaphylaxis treatment of adults and children in the UK,"July 18, 2025 8:01 AM EDT
EURneffy® approved as the first needle-free anaphylaxis treatment of adults and children in the UK
View this release →
Or 
click here
 to view all releases.
You are subscribed to ALK Investor Relations' email alerts.
To unsubscribe from all alerts, please 
click here
.
ALK
Bøge Allé 6-8  DK-2970, Hørsholm,  , Denmark
Service provided by Notified

",gmail,,1,1,EURneffy® approved as the first needle-free anaphylaxis treatment of adults and children in the UK,"July 18, 2025 8:01 AM EDT EURneffy® approved as the first needle-free anaphylaxis treatment of adults and children in the UK View this release → Or click here to view all releases. You are subscribed to ALK Investor Relations' email alerts. To unsubscribe from all alerts, please click here . ALK Bøge Allé 6-8 DK-2970, Hørsholm, , Denmark Service provided by Notified"
1989e512671d583d,ALK,unknown,2025-08-12,2025-08-20T12:31:18+00:00,ALK upgrades its full-year revenue outlook,"August 12, 2025 8:45 AM EDT
ALK upgrades its full-year revenue outlook  
View this release →
Or 
click here
 to view all releases.
You are subscribed to ALK Investor Relations' email alerts.
To unsubscribe from all alerts, please 
click here
.
ALK
Bøge Allé 6-8  DK-2970, Hørsholm,  , Denmark
Service provided by Notified

",gmail,,1,1,ALK upgrades its full-year revenue outlook,"August 12, 2025 8:45 AM EDT ALK upgrades its full-year revenue outlook View this release → Or click here to view all releases. You are subscribed to ALK Investor Relations' email alerts. To unsubscribe from all alerts, please click here . ALK Bøge Allé 6-8 DK-2970, Hørsholm, , Denmark Service provided by Notified"
198a350e0725f826,Ericsson,unknown,2025-08-13,2025-08-20T12:21:17+00:00,Activate your Ericsson subscription,"[*] 
Thank you for subscribing to Ericsson press releases.



To activate the subscription, please click the following link:

		
Confirm email adress


Ericsson press information distributed by Cision. 

",gmail,,1,1,Activate your Ericsson subscription,"[*] Thank you for subscribing to Ericsson press releases. To activate the subscription, please click the following link: Confirm email adress Ericsson press information distributed by Cision."
198a3515dc40adf2,Ericsson,unknown,2025-08-13,2025-08-20T12:21:18+00:00,Welcome to Ericsson,"[*] 
Welcome as a subscriber to Ericsson press releases.

As of today you will receive Ericsson press releases to this e-mail address.


Ericsson press information distributed by Cision. 


To unsubscribe, please click on the link below.(If you can't click on the link, copy the link and paste it into your browser)

Cancel subscription

",gmail,,1,1,Welcome to Ericsson,"[*] Welcome as a subscriber to Ericsson press releases. As of today you will receive Ericsson press releases to this e-mail address. Ericsson press information distributed by Cision. To unsubscribe, please click on the link below.(If you can't click on the link, copy the link and paste it into your browser) Cancel subscription"
198a3549336a64d5,Fabege,unknown,2025-08-13,2025-08-20T12:21:25+00:00,Welcome,"
Welcome as subscriber at Fabege

From now on, you will receive information from Fabege to this e-mail address,

To deactivate your subscription use the link below (if you cannot click it, copy it and paste it into a Web browser)

https://publish.ne.cision.com/Subscriber/Index/B2AEEB5ED3F7E0ED408E4E6A701B6D7B
",gmail,,1,1,Welcome,"Welcome as subscriber at Fabege From now on, you will receive information from Fabege to this e-mail address, To deactivate your subscription use the link below (if you cannot click it, copy it and paste it into a Web browser)"
198a36a3358665a8,HEXPOL AB Alerting Service,unknown,2025-08-13,2025-08-20T12:21:46+00:00,Verify your request for Hexpol Corporate Alert Service," 
 Thank you for your request.
 Please click below button to complete the process:
 
Yes, I confirm
 
 Kind regards,
 Investor Relations Team 
 
This service is brought to you by 
IDX

",gmail,,1,1,Verify your request for Hexpol Corporate Alert Service,"Thank you for your request. Please click below button to complete the process: Yes, I confirm Kind regards, Investor Relations Team This service is brought to you by IDX"
198a36aa285484b7,HEXPOL AB Alerting Service,unknown,2025-08-13,2025-08-20T12:21:47+00:00,Verify your request for Hexpol Corporate Alert Service," 
 Thank you for your request.
 Please click below button to complete the process:
 
Yes, I confirm
 
 Kind regards,
 Investor Relations Team 
 
This service is brought to you by 
IDX

",gmail,,1,1,Verify your request for Hexpol Corporate Alert Service,"Thank you for your request. Please click below button to complete the process: Yes, I confirm Kind regards, Investor Relations Team This service is brought to you by IDX"
198a36ad1cff24e2,HEXPOL AB Alerting Service,unknown,2025-08-13,2025-08-20T12:21:48+00:00,Subscription confirmation for Hexpol Corporate Alert Service," 
 Thank you. Your registration is now complete for following alerts:
 
Custom News
 
•
Press Releases
 
•
Reports and Presentations
 
 
 Please click below button to unsubscribe, or to update your preferences:
Click here
 Kind regards,
 Investor Relations Team 
 
This service is brought to you by 
IDX

",gmail,,1,1,Subscription confirmation for Hexpol Corporate Alert Service,"Thank you. Your registration is now complete for following alerts: Custom News • Press Releases • Reports and Presentations Please click below button to unsubscribe, or to update your preferences: Click here Kind regards, Investor Relations Team This service is brought to you by IDX"
198a36bcdeebeea1,HEXPOL AB Alerting Service,unknown,2025-08-13,2025-08-20T12:21:49+00:00,Verify your request for Hexpol Corporate Alert Service," 
 Thank you for your request.
 Please click below button to complete the process:
 
Yes, I confirm
 
 Kind regards,
 Investor Relations Team 
 
This service is brought to you by 
IDX

",gmail,,1,1,Verify your request for Hexpol Corporate Alert Service,"Thank you for your request. Please click below button to complete the process: Yes, I confirm Kind regards, Investor Relations Team This service is brought to you by IDX"
198a36bf57913c84,HEXPOL AB Alerting Service,unknown,2025-08-13,2025-08-20T12:21:50+00:00,Subscription confirmation for Hexpol Corporate Alert Service," 
 Thank you. Your registration is now complete for following alerts:
 
Custom News
 
•
Press Releases
 
•
Reports and Presentations
 
 
 Please click below button to unsubscribe, or to update your preferences:
Click here
 Kind regards,
 Investor Relations Team 
 
This service is brought to you by 
IDX

",gmail,,1,1,Subscription confirmation for Hexpol Corporate Alert Service,"Thank you. Your registration is now complete for following alerts: Custom News • Press Releases • Reports and Presentations Please click below button to unsubscribe, or to update your preferences: Click here Kind regards, Investor Relations Team This service is brought to you by IDX"
198a3b44c1ba242c,JM,unknown,2025-08-13,2025-08-20T12:22:03+00:00,Welcome,"
Welcome as subscriber at JM

From now on, you will receive information from JM to this e-mail address. 

To unsubscribe, please click on the link below.(If you can't click on the link, copy the link and paste it into your browser)

https://publish.ne.cision.com/Subscriber/Index/EA5908A7F2E73E51408E4E6A701B6D7B
",gmail,,1,1,Welcome,"Welcome as subscriber at JM From now on, you will receive information from JM to this e-mail address. To unsubscribe, please click on the link below.(If you can't click on the link, copy the link and paste it into your browser)"
198a7c79aed8b382,Lundinmining,unknown,2025-08-14,2025-08-20T12:11:28+00:00,Email validation for Lundin Mining Corporation required,"



Thank you for subscribing to receive email alerts from Lundin Mining Corporation.


To validate your subscription, click or paste the URL below into your browser:


https://lundinmining.mediaroom.com/email-alerts?validate=jXCkRhNc1KRXRSyA2ES9y4GZBjLyavaT&hide_page_content=1
[ Form submitted from: 
https://lundinmining.mediaroom.com/index.php?type=1&s=34170
 ]





",gmail,,1,1,Email validation for Lundin Mining Corporation required,"Thank you for subscribing to receive email alerts from Lundin Mining Corporation. To validate your subscription, click or paste the URL below into your browser: [ Form submitted from: ]"
198a7c7fca745996,Lundinmining,unknown,2025-08-14,2025-08-20T12:11:29+00:00,Email validation for Lundin Mining Corporation required,"



Thank you for subscribing to receive email alerts from Lundin Mining Corporation.


To validate your subscription, click or paste the URL below into your browser:


https://lundinmining.mediaroom.com/email-alerts?validate=PcDdbhWzxaRnRby0dYzXfHZ2Q2KsFq2O&hide_page_content=1
[ Form submitted from: 
https://lundinmining.mediaroom.com/index.php?type=1&s=34170
 ]





",gmail,,1,1,Email validation for Lundin Mining Corporation required,"Thank you for subscribing to receive email alerts from Lundin Mining Corporation. To validate your subscription, click or paste the URL below into your browser: [ Form submitted from: ]"
198a7c861eb5477b,Lundinmining,unknown,2025-08-14,2025-08-20T12:11:30+00:00,Email validation for Lundin Mining Corporation required,"



Thank you for subscribing to receive email alerts from Lundin Mining Corporation.


To validate your subscription, click or paste the URL below into your browser:


https://lundinmining.mediaroom.com/email-alerts?validate=KH4srTreL6SlRY9wcs0dsTLP2Y-Q0u2J&hide_page_content=1
[ Form submitted from: 
https://lundinmining.mediaroom.com/index.php?type=1&s=34170
 ]





",gmail,,1,1,Email validation for Lundin Mining Corporation required,"Thank you for subscribing to receive email alerts from Lundin Mining Corporation. To validate your subscription, click or paste the URL below into your browser: [ Form submitted from: ]"
198a7caff9749d74,Lundinmining,unknown,2025-08-14,2025-08-20T12:11:31+00:00,Email validation for Lundin Mining Corporation required,"



Thank you for subscribing to receive email alerts from Lundin Mining Corporation.


To validate your subscription, click or paste the URL below into your browser:


https://lundinmining.mediaroom.com/email-alerts?validate=hbCVvAeGcqSpRfdzrmwtYNiII8AGRkFw&hide_page_content=1
[ Form submitted from: 
https://lundinmining.mediaroom.com/index.php?type=1&s=34170
 ]





",gmail,,1,1,Email validation for Lundin Mining Corporation required,"Thank you for subscribing to receive email alerts from Lundin Mining Corporation. To validate your subscription, click or paste the URL below into your browser: [ Form submitted from: ]"
198a7cb3a53f14a5,Lundinmining,unknown,2025-08-14,2025-08-20T12:11:32+00:00,Email validation for Lundin Mining Corporation required,"



Thank you for subscribing to receive email alerts from Lundin Mining Corporation.


To validate your subscription, click or paste the URL below into your browser:


https://lundinmining.mediaroom.com/email-alerts?validate=7nA9Y4CBdaS-RVvpt7qr2GH78nOv86NS&hide_page_content=1
[ Form submitted from: 
https://lundinmining.mediaroom.com/index.php?type=1&s=34170
 ]





",gmail,,1,1,Email validation for Lundin Mining Corporation required,"Thank you for subscribing to receive email alerts from Lundin Mining Corporation. To validate your subscription, click or paste the URL below into your browser: [ Form submitted from: ]"
198a7d5f5038b776,NCC,unknown,2025-08-14,2025-08-20T12:11:45+00:00,Confirm your subscription,"[*] 
You have subscribed to receive information from NCC in Sweden, Denmark, Finland or Norway. If you have also subscribed to NCC AB, you will receive two emails to activate the subscriptions.



To activate your subscription for NCC in Sweden, Denmark, Finland or Norway, please activate your email by clicking on the link below:

		
Confirm email address




",gmail,,1,1,Confirm your subscription,"[*] You have subscribed to receive information from NCC in Sweden, Denmark, Finland or Norway. If you have also subscribed to NCC AB, you will receive two emails to activate the subscriptions. To activate your subscription for NCC in Sweden, Denmark, Finland or Norway, please activate your email by clicking on the link below: Confirm email address"
198a7d5f9680a835,NCC,unknown,2025-08-14,2025-08-20T12:11:46+00:00,Confirm your subscription,"[*] 
You have subscribed to receive information from NCC in Sweden, Denmark, Finland or Norway. If you have also subscribed to NCC AB, you will receive two emails to activate the subscriptions.



To activate your subscription for NCC in Sweden, Denmark, Finland or Norway, please activate your email by clicking on the link below:

		
Confirm email address




",gmail,,1,1,Confirm your subscription,"[*] You have subscribed to receive information from NCC in Sweden, Denmark, Finland or Norway. If you have also subscribed to NCC AB, you will receive two emails to activate the subscriptions. To activate your subscription for NCC in Sweden, Denmark, Finland or Norway, please activate your email by clicking on the link below: Confirm email address"
198a7d62de913680,NCC,unknown,2025-08-14,2025-08-20T12:11:47+00:00,Confirm your subscription,"[*] 
You have subscribed to receive information from NCC in Sweden, Denmark, Finland or Norway. If you have also subscribed to NCC AB, you will receive two emails to activate the subscriptions.



To activate your subscription for NCC in Sweden, Denmark, Finland or Norway, please activate your email by clicking on the link below:

		
Confirm email address




",gmail,,1,1,Confirm your subscription,"[*] You have subscribed to receive information from NCC in Sweden, Denmark, Finland or Norway. If you have also subscribed to NCC AB, you will receive two emails to activate the subscriptions. To activate your subscription for NCC in Sweden, Denmark, Finland or Norway, please activate your email by clicking on the link below: Confirm email address"
198a7d62e6115d5d,NCC,unknown,2025-08-14,2025-08-20T12:11:48+00:00,Confirm your subscription,"[*] 
You have subscribed to receive information from NCC in Sweden, Denmark, Finland or Norway. If you have also subscribed to NCC AB, you will receive two emails to activate the subscriptions.



To activate your subscription for NCC in Sweden, Denmark, Finland or Norway, please activate your email by clicking on the link below:

		
Confirm email address




",gmail,,1,1,Confirm your subscription,"[*] You have subscribed to receive information from NCC in Sweden, Denmark, Finland or Norway. If you have also subscribed to NCC AB, you will receive two emails to activate the subscriptions. To activate your subscription for NCC in Sweden, Denmark, Finland or Norway, please activate your email by clicking on the link below: Confirm email address"
198a7d62ebf96eb9,NCC,unknown,2025-08-14,2025-08-20T12:11:49+00:00,Confirm your subscription,"[*] 
You have subscribed to receive information from NCC in Sweden, Denmark, Finland or Norway. If you have also subscribed to NCC AB, you will receive two emails to activate the subscriptions.



To activate your subscription for NCC in Sweden, Denmark, Finland or Norway, please activate your email by clicking on the link below:

		
Confirm email address




",gmail,,1,1,Confirm your subscription,"[*] You have subscribed to receive information from NCC in Sweden, Denmark, Finland or Norway. If you have also subscribed to NCC AB, you will receive two emails to activate the subscriptions. To activate your subscription for NCC in Sweden, Denmark, Finland or Norway, please activate your email by clicking on the link below: Confirm email address"
198a7d62f06f9c69,NCC,unknown,2025-08-14,2025-08-20T12:11:49+00:00,Confirm your subscription,"[*] 
You have subscribed to receive information from NCC in Sweden, Denmark, Finland or Norway. If you have also subscribed to NCC AB, you will receive two emails to activate the subscriptions.



To activate your subscription for NCC in Sweden, Denmark, Finland or Norway, please activate your email by clicking on the link below:

		
Confirm email address




",gmail,,1,1,Confirm your subscription,"[*] You have subscribed to receive information from NCC in Sweden, Denmark, Finland or Norway. If you have also subscribed to NCC AB, you will receive two emails to activate the subscriptions. To activate your subscription for NCC in Sweden, Denmark, Finland or Norway, please activate your email by clicking on the link below: Confirm email address"
198a7d631a76488c,NCC,unknown,2025-08-14,2025-08-20T12:11:51+00:00,Confirm your subscription,"[*] 
You have subscribed to NCC AB. If you have also subscribed to local information per country, you will receive two emails to activate the subscriptions.



To activate your subscription for NCC AB, please activate your email by clicking on the link below:

		
Confirm email address




",gmail,,1,1,Confirm your subscription,"[*] You have subscribed to NCC AB. If you have also subscribed to local information per country, you will receive two emails to activate the subscriptions. To activate your subscription for NCC AB, please activate your email by clicking on the link below: Confirm email address"
198a7d66b433e93c,NCC,unknown,2025-08-14,2025-08-20T12:11:53+00:00,Welcome as a subscriber,"[*] 
Welcome as subscriber at NCC

From now on, you will receive information from NCC to this e-mail address.





To unsubscribe, please click on the link below.(If you can't click on the link, copy the link and paste it into your browser)

Cancel subscription

",gmail,,1,1,Welcome as a subscriber,"[*] Welcome as subscriber at NCC From now on, you will receive information from NCC to this e-mail address. To unsubscribe, please click on the link below.(If you can't click on the link, copy the link and paste it into your browser) Cancel subscription"
198a7d69f0bf7e9c,NCC,unknown,2025-08-14,2025-08-20T12:11:54+00:00,Welcome as a subscriber,"[*] 
Welcome as subscriber at NCC

From now on, you will receive information from NCC to this e-mail address.





To unsubscribe, please click on the link below.(If you can't click on the link, copy the link and paste it into your browser)

Cancel subscription

",gmail,,1,1,Welcome as a subscriber,"[*] Welcome as subscriber at NCC From now on, you will receive information from NCC to this e-mail address. To unsubscribe, please click on the link below.(If you can't click on the link, copy the link and paste it into your browser) Cancel subscription"
198a7e2166c57870,Nordea,unknown,2025-08-14,2025-08-20T12:12:11+00:00,Opt-In,"
Thank you for subscribing to Cisions services!

To activate the subscription, we request that you confirm your e-mail address. Do this by clicking on this link:

https://publish.ne.cision.com/Subscription/ConfirmSubscription/3A2790674290C83A1B44B93DCC40C27832BA879E8C3A3D2F
",gmail,,1,1,Opt-In,"Thank you for subscribing to Cisions services! To activate the subscription, we request that you confirm your e-mail address. Do this by clicking on this link:"
198a7e24ecebad19,Nordea,unknown,2025-08-14,2025-08-20T12:12:12+00:00,Welcome,"
Welcome as subscriber at Cision

From now on, you will receive information from Cision to this e-mail address. 

To unsubscribe, please click on the link below.(If you can't click on the link, copy the link and paste it into your browser)

https://publish.ne.cision.com/Subscriber/Index/3A2790674290C83A408E4E6A701B6D7B
",gmail,,1,1,Welcome,"Welcome as subscriber at Cision From now on, you will receive information from Cision to this e-mail address. To unsubscribe, please click on the link below.(If you can't click on the link, copy the link and paste it into your browser)"
198c7e6f26e69c90,Google,unknown,2025-08-20,2025-08-20T14:41:19+00:00,Security alert,"[image: Google]
You allowed Google Auth Library access to some of your Google Account data


rs.newsfeed.123@gmail.com

If you didn’t allow Google Auth Library access to some of your Google
Account data, someone else may be trying to access your Google Account data.

Take a moment now to check your account activity and secure your account.
Check activity
<https://accounts.google.com/AccountChooser?Email=rs.newsfeed.123@gmail.com&continue=https://myaccount.google.com/alert/nt/1755700456000?rfn%3D127%26rfnc%3D1%26eid%3D-5585195332170748941%26et%3D0>
To make changes at any time to the access that Google Auth Library has to
your data, go to your Google Account
<https://accounts.google.com/AccountChooser?Email=rs.newsfeed.123@gmail.com&continue=https://myaccount.google.com/connections/overview/AXgE0HME9tmjw1-SMtaQEKFM2ctwhs_2lwjHzAO_fJXBmwek5tYiAxYHbktTGOQMeQB-Jw6cTj6m9S7adbtTPl5Lpg4?utm_source%3Dsec_alert%26utm_medium%3Demail_notification%26force_all%3Dtrue>
You can also see security activity at
https://myaccount.google.com/notifications
You received this email to let you know about important changes to your
Google Account and services.
© 2025 Google Ireland Ltd., Gordon House, Barrow Street, Dublin 4, Ireland
",gmail,,1,1,Security alert,"[image: Google] You allowed Google Auth Library access to some of your Google Account data If you didn’t allow Google Auth Library access to some of your Google Account data, someone else may be trying to access your Google Account data. Take a moment now to check your account activity and secure your account. Check activity To make changes at any time to the access that Google Auth Library has to your data, go to your Google Account You can also see security activity at You received this email to let you know about important changes to your Google Account and services. © 2025 Google Ireland Ltd., Gordon House, Barrow Street, Dublin 4, Ireland"
198cb08c08a6a343,Nanoform Finland Oyj,unknown,2025-08-21,2025-08-21T05:11:19+00:00,"Nanoform Q2 2025 report: Continued progress on many fronts, supportive first preliminary pivotal nanoenzalutamide study results","





Nanoform Q2 2025 report: Continued progress on many fronts, supportive first preliminary pivotal nanoenzalutamide study results





































            Published: 2025-08-21 07:10:00 CEST
        








Nanoform Finland Oyj - Half year financial report
Nanoform Q2 2025 report: Continued progress on many fronts, supportive first preliminary pivotal nanoenzalutamide study results
Nanoform Finland Plc | Company Release | August 21, 2025 at 08:10:00 EEST


First preliminary pivotal study results supportive for project Nanoenzalutamide to continue to progress towards the markets. Growth in number of signed new projects, revenue and other operating income continued, while operating costs fell slightly, leading to improved cash flow. Customer payments year-to-date already exceed last year's revenue. Fimea inspection date for commercial license set for end of 3Q. All 2025 near term targets are on track.


4-6/2025 key financials
Revenue grew to EUR 0.67 million, compared with EUR 0.65 million in 4-6/2024.
The gross profit increased to EUR 0.66 million, with the gross margin rising to 98% (EUR 0.50 million, 77%).
Total operating costs* decreased by -5% to EUR 6.1 million (EUR 6.4 million).
The number of employees grew by 1% to 175 (174) compared with one year ago.
EBITDA improved to EUR -5.1 million (EUR -5.5 million).
The operating free cash flow improved to EUR -5.2 million (EUR -5.7 million).
Basic EPS was EUR -0.07 (EUR -0.06).
Cash position** was 33.3 million on June 30, 2025 (EUR 51.5 million).
1-6/2025 key financials
Revenue grew by 23% to EUR 1.54 million, stemming from 39 different customer projects (EUR 1.25 million, 28 projects in 1-6/2024).
The gross profit increased to EUR 1.4 million, with a gross margin of 89% (EUR 1.0 million, 79%).
The number of employees grew to 175 (174).
Total operating costs* decreased by -4% to EUR 12.3 million (EUR 12.9 million).
EBITDA improved to EUR -10.0 million (EUR -11.2 million).
The operating loss was EUR -11.6 million (EUR -12.8 million).
The operating free cash flow improved to EUR -10.4 million (-11.7 million).
Basic EPS was EUR -0.13 (EUR -0.15).
(Numbers in brackets refer to the corresponding last year reporting period, unless otherwise mentioned.)
* Defined as materials & services expenses, employee benefit expenses, and other operating expenses.
** Including Treasury bills. Part of the cash has been invested in short-term government bonds.
CEO's review
Nanoform continues to progress on many fronts. During the first half of 2025 we've seen significant scale-up, automation and industrialization achievements on both our small molecule and biologics technology platforms, new patents have been granted, proposals sent & projects won continued to grow, likewise revenue and other income. Customer payments year-to-date, including the first milestone payments related to our product kernels already exceed last year's revenues, costs are down and our cash burn has continued to improve steadily. The discussions and work around our product kernels continue with existing and prospective partners and we are pleased with Business Finland's decision to grant us a loan to support our development of Nanoapalutamide.
We received the first preliminary results from the first arm of the pivotal clinical study of nanoenzalutamide. The results demonstrated that nanoenzalutamide in fasted study subjects showed matching plasma concentration compared to the reference product, and slightly low peak plasma concentration. Nanoform and the ONConcept
®
 consortium’s initial assessment is that the results are supportive for nanoenzalutamide to progress to the markets underpinned by an adjusted regulatory strategy. These new clinical results strengthen our understanding of how the nanoforming technology performs in human biology and its potential to deliver patient-centric therapies. Reducing high initial plasma concentrations whilst still achieving similar bioavailability as amorphous solid dispersions can be a significant benefit in oral drug delivery.
I'm pleased by the fact that our Biologics technology offering continues to garner increased interest from the pharma industry. Takeda presented results related to their project with Nanoform's Biologics technology at the Drug Delivery Forum in Berlin. The presentation entitled, “A Novel Nanoformed Presentation of AAT for the Treatment of Pulmonary Emphysema in AAT Deficient Patients,” showed nanoforming as an alternative administration strategy for an AAT replacement therapy, based on a novel solidification platform from Nanoform. Their comparison with other methods such as spray drying showed that the nanoformed particulate material could deposit significantly higher amounts of AAT within the alveolar system.
At the same forum Nanoform presented the successful generation of nanotrastuzumab, a high concentration nanoformulation of trastuzumab, suitable for subcutaneous injection, enabling more than 400mg/ml dose in a single 2mL syringe, instead of intravenous injections.
During the past year we've worked on more than 40 different customer projects. These cover both small molecules and biologics, and range across multiple therapy areas and delivery methods. I remain encouraged by the broad applicability of our nanoparticles and nanoformulations. Not all customer projects progress, for many reasons, however, the momentum I see in many of these projects and the fact that our customers return makes me confident that we will see some of these ongoing customer projects enter the clinic. This dynamic validates our strategy to work with many different companies and APIs, to not become dependent on any single project.
For Nanoform the last years have been about making large investments and building a capable organization. The coming years is about preparing to launch nanoformed products together with partners onto the global markets. We are ready for the challenge. I look forward with confidence and excitement to the coming years. None of this can be done without our amazing employees and great partners. My sincere THANK YOU to you all for your continued dedication to Nanoform and for the inspiring and innovative work for which we’re known.
Best Regards,
Prof. Edward Hæggström, CEO Nanoform
Significant events during 1-6/2025
In January our R&D team further scaled-up the CESS® technology by a factor 20x on nanoenzalutamide, indicating that after tech-transfer into GMP, we will be ready for the estimated 1000kg+ commercial demand when launched globally. This technology development also supports the commercial needs of nanoapalutamide and nanoencorafenib.
In March, a new US global major pharma company was signed.
At the end of March we filed for a commercial license for nanoenzalutamide to Fimea.
In March a lead investor signed a term sheet around nanoencorafenib.
During the quarter we successfully implemented and went live with TrackWise eQMS (digital quality management system).
Nanoform has earlier filed patent applications for its small molecule controlled crystallization platform that produces crystalline polymer embedded nanoparticles (cPENs
TM
). During the first quarter the first patent family member was granted in the United States by the USPTO. This is evidence for the significant opportunity Nanoform has to generate valuable IP leveraging its platforms for nanoformulations and products. The cPEN
TM
 formulation platform is utilized for nanoenzalutamide, nanoapalutamide, and nanoencorafenib, among other internal and ongoing customer projects
Nanoform's AGM was held on April 15, 2025. 42 shareholders representing 58.9% of all outstanding shares and votes were represented at the meeting (for more information see section AGM decisions).
In April, Nanoform won a new grant from the Gates Foundation to work on several of the foundation’s drug development projects.
In April, our Bio R&D team achieved a 10x scale-up of our Biologics technology, by producing 2kg in one continuous run on our pilot GMP line. This supports our efforts to show the commercial value the technology can bring to the fast growing field of high-concentration subcutaneous injections of monoclonal antibodies (mAbs).
In April we successfully concluded our GMP campaign of nanoenzalutamide. 100kg material was produced and shipped to Bluepharma, where hundreds of thousands of tablets are produced. This successful campaign has resulted in a validated process for nanoenzalutamide. This supports our upcoming regulatory filings.
In May Nanoform signed a letter of intent to establish, in collaboration with two specialist healthcare investors, BRAFMed Ltd, a new company to progress the clinical development and outlicensing of Nanoencorafenib
In June Takeda presented results related to their project with Nanoform's Biologics technology at the Drug Delivery Forum in Berlin. The presentation entitled “A Novel Nanoformed Presentation of AAT for the Treatment of Pulmonary Emphysema in AAT Deficient Patients,” shared results from the study, which investigated Nanoformed A1AT, a respirable dry powder for inhalation, as an alternative administration strategy for an AAT replacement therapy, based on a novel solidification platform from Nanoform. Inhaled A1AT could help achieving much higher A1AT levels in the epithelium lining fluid while offering a more patient centric formulation.
In June at DDF in Berlin Nanoform presented the successful generation of nanotrastuzumab, a high concentration nanoformulation of trastuzumab, suitable for subcutaneous injection, enabling more than 400mg/ml dose in a single 2mL syringe, instead of intravenous injections.
In June Nanoform announced that it together with its ONConcept® Consortium partners (Bluepharma, Helm, Welding) had started pivotal relative bioequivalence studies of Nanoenzalutamide. The purpose of the studies (fed/fasted, EU&US) is to achieve bioequivalence for a single nanoformed 160 mg tablet dose with four Xtandi® 40 mg film-coated tablets.
In June Business Finland approved a EUR 5m R&D loan to support the clinical development of nanoapalutamide, The loan covers up to 50% of the costs associated with the clinical development program through to the pivotal bioequivalence study. The interest rate on the loan is three percentage points below the base interest rate, or at least one percent, and no collateral is required. The loan period is ten years. During the first five years only interest is paid.
Significant events after 1-6/2025
In August Nanoform received the first preliminary results from the first arm of the pivotal clinical study of nanoenzalutamide, a nanocrystalline-enabled tablet formulation of enzalutamide developed using Nanoform’s proprietary CESS
®
 technology. Nanoenzalutamide is being developed in partnership with the ONConcept
®
 Consortium (Bluepharma, Helm, Welding). This read-out was from the first arm of the pivotal study, a single-dose, randomized, open-label, parallel, bioequivalence study of nanoenzalutamide 160 mg film-coated tablets and Xtandi® (enzalutamide) 4 x 40 mg film-coated tablets (Astellas Pharma Europe B.V.) in healthy male volunteers under fasting conditions. The results demonstrated that nanoenzalutamide in fasted study subjects showed matching plasma concentration (“AUC”) compared to the reference product, and slightly low peak plasma concentration (“Cmax”). Nanoform and the ONConcept
®
 consortium’s initial assessment is that the results are supportive for nanoenzalutamide to progress to the markets underpinned by an adjusted regulatory strategy. The ongoing clinical study continues with dosing under fed conditions as planned. Nanoform and ONConcept
®
 remain confident that the unique patient-centric crystalline one tablet formulation will offer an attractive product for partners and patients, with the opportunity to potentially launch prior to other generic products relying on the amorphous solid dispersion formulation that is patent protected until 2033. Nanoform does not currently expect there to be material changes to earlier volume- and commercial estimates provided in connection with Nanoform’s 1Q report.
Company near-term business targets for 2025
To sign development and license/commercial supply agreements on several product kernels during 2025
First pivotal bioequivalence study with nanoformed medicine
Increased number of non-GMP and GMP projects signed in 2025 vs 2024
Improved free cash flow in 2025 vs 2024
Company mid-term business targets 2030
To be announced during 2025 in conjunction with Capital Markets Day.
Nanoform’s Q2 2025 report and management presentation can be found at: 
https://nanoform.com/en/financial-reports-and-presentations/
Nanoform online presentation and conference call August 21, 2025, at 3:00 p.m. Helsinki time / 2:00 p.m. Stockholm time:
The company will hold an online presentation and conference call the same day at 3.00 p.m. Finnish time / 2.00 p.m. Swedish time. Nanoform will be represented by CEO Edward Hæggström, CFO Albert Hæggström, CCO Christian Jones and CDO/General Counsel Peter Hänninen. The presentation will be delivered in English.
The presentation will be broadcasted live and participants may access the event via audiocast and teleconference through the following link:
https://investorcaller.com/events/nanoform/nanoform-q2-report-2025
To participate in the event, attendees are required to register. To join the Q&A session, attendees must access the teleconference by dialing in. Upon registration, participants will receive a dial-in number, a conference ID, and a personal User ID to access the conference. Please note that questions can only be submitted through the teleconference line.
For further information, please contact:
Dr. Edward Hæggström, CEO
edward.haeggstrom@nanoform.com
+358 (0)29 370 0150
Henri von Haartman, Director of Investor Relations
hvh@nanoform.com
+46 (0)7686 650 11
About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services, from pre-clinical to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: DNB Carnegie Investment Bank AB, +46 (0)73 856 42 65, 
certifiedadviser@carnegie.se
. For more information, please visit 
www.nanoform.com
.
Forward-Looking Statements
This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform’s strategy, business plans and focus. The words “may”, “will”, “could”, “would”, “should”, “expect”, “plan”, “anticipate”, “intend”, believe”, “estimate”, “predict”, “project”, “potential”, “continue”, “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform’s business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks described in the Report of the Board of Directors and Financial Statements for the year ended December 31, 2024 as well as our other past disclosures. Nanoform cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Nanoform’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.












Attachments:


Nanoform Q2 Interim Report 2025.pdf













        This email message was delivered to rs.newsfeed.123@gmail.com
        





			Cancel this subscription
		















                            This news release was distributed by Company News System, 
nasdaq.com/european-market-activity/news/company-news



















",gmail,,1,1,"Nanoform Q2 2025 report: Continued progress on many fronts, supportive first preliminary pivotal nanoenzalutamide study results","Nanoform Q2 2025 report: Continued progress on many fronts, supportive first preliminary pivotal nanoenzalutamide study results Published: 2025-08-21 07:10:00 CEST Nanoform Finland Oyj - Half year financial report Nanoform Q2 2025 report: Continued progress on many fronts, supportive first preliminary pivotal nanoenzalutamide study results Nanoform Finland Plc | Company Release | August 21, 2025 at 08:10:00 EEST First preliminary pivotal study results supportive for project Nanoenzalutamide to continue to progress towards the markets. Growth in number of signed new projects, revenue and other operating income continued, while operating costs fell slightly, leading to improved cash flow. Customer payments year-to-date already exceed last year's revenue. Fimea inspection date for commercial license set for end of 3Q. All 2025 near term targets are on track. 4-6/2025 key financials Revenue grew to EUR 0.67 million, compared with EUR 0.65 million in 4-6/2024. The gross profit increased to EUR 0.66 million, with the gross margin rising to 98% (EUR 0.50 million, 77%). Total operating costs* decreased by -5% to EUR 6.1 million (EUR 6.4 million). The number of employees grew by 1% to 175 (174) compared with one year ago. EBITDA improved to EUR -5.1 million (EUR -5.5 million). The operating free cash flow improved to EUR -5.2 million (EUR -5.7 million). Basic EPS was EUR -0.07 (EUR -0.06). Cash position** was 33.3 million on June 30, 2025 (EUR 51.5 million). 1-6/2025 key financials Revenue grew by 23% to EUR 1.54 million, stemming from 39 different customer projects (EUR 1.25 million, 28 projects in 1-6/2024). The gross profit increased to EUR 1.4 million, with a gross margin of 89% (EUR 1.0 million, 79%). The number of employees grew to 175 (174). Total operating costs* decreased by -4% to EUR 12.3 million (EUR 12.9 million). EBITDA improved to EUR -10.0 million (EUR -11.2 million). The operating loss was EUR -11.6 million (EUR -12.8 million). The operating free cash flow improved to EUR -10.4 million (-11.7 million). Basic EPS was EUR -0.13 (EUR -0.15). (Numbers in brackets refer to the corresponding last year reporting period, unless otherwise mentioned.) * Defined as materials & services expenses, employee benefit expenses, and other operating expenses. ** Including Treasury bills. Part of the cash has been invested in short-term government bonds. CEO's review Nanoform continues to progress on many fronts. During the first half of 2025 we've seen significant scale-up, automation and industrialization achievements on both our small molecule and biologics technology platforms, new patents have been granted, proposals sent & projects won continued to grow, likewise revenue and other income. Customer payments year-to-date, including the first milestone payments related to our product kernels already exceed last year's revenues, costs are down and our cash burn has continued to improve steadily. The discussions and work around our product kernels continue with existing and prospective partners and we are pleased with Business Finland's decision to grant us a loan to support our development of Nanoapalutamide. We received the first preliminary results from the first arm of the pivotal clinical study of nanoenzalutamide. The results demonstrated that nanoenzalutamide in fasted study subjects showed matching plasma concentration compared to the reference product, and slightly low peak plasma concentration. Nanoform and the ONConcept ® consortium’s initial assessment is that the results are supportive for nanoenzalutamide to progress to the markets underpinned by an adjusted regulatory strategy. These new clinical results strengthen our understanding of how the nanoforming technology performs in human biology and its potential to deliver patient-centric therapies. Reducing high initial plasma concentrations whilst still achieving similar bioavailability as amorphous solid dispersions can be a significant benefit in oral drug delivery. I'm pleased by the fact that our Biologics technology offering continues to garner increased interest from the pharma industry. Takeda presented results related to their project with Nanoform's Biologics technology at the Drug Delivery Forum in Berlin. The presentation entitled, “A Novel Nanoformed Presentation of AAT for the Treatment of Pulmonary Emphysema in AAT Deficient Patients,” showed nanoforming as an alternative administration strategy for an AAT replacement therapy, based on a novel solidification platform from Nanoform. Their comparison with other methods such as spray drying showed that the nanoformed particulate material could deposit significantly higher amounts of AAT within the alveolar system. At the same forum Nanoform presented the successful generation of nanotrastuzumab, a high concentration nanoformulation of trastuzumab, suitable for subcutaneous injection, enabling more than 400mg/ml dose in a single 2mL syringe, instead of intravenous injections. During the past year we've worked on more than 40 different customer projects. These cover both small molecules and biologics, and range across multiple therapy areas and delivery methods. I remain encouraged by the broad applicability of our nanoparticles and nanoformulations. Not all customer projects progress, for many reasons, however, the momentum I see in many of these projects and the fact that our customers return makes me confident that we will see some of these ongoing customer projects enter the clinic. This dynamic validates our strategy to work with many different companies and APIs, to not become dependent on any single project. For Nanoform the last years have been about making large investments and building a capable organization. The coming years is about preparing to launch nanoformed products together with partners onto the global markets. We are ready for the challenge. I look forward with confidence and excitement to the coming years. None of this can be done without our amazing employees and great partners. My sincere THANK YOU to you all for your continued dedication to Nanoform and for the inspiring and innovative work for which we’re known. Best Regards, Prof. Edward Hæggström, CEO Nanoform Significant events during 1-6/2025 In January our R&D team further scaled-up the CESS® technology by a factor 20x on nanoenzalutamide, indicating that after tech-transfer into GMP, we will be ready for the estimated 1000kg+ commercial demand when launched globally. This technology development also supports the commercial needs of nanoapalutamide and nanoencorafenib. In March, a new US global major pharma company was signed. At the end of March we filed for a commercial license for nanoenzalutamide to Fimea. In March a lead investor signed a term sheet around nanoencorafenib. During the quarter we successfully implemented and went live with TrackWise eQMS (digital quality management system). Nanoform has earlier filed patent applications for its small molecule controlled crystallization platform that produces crystalline polymer embedded nanoparticles (cPENs TM ). During the first quarter the first patent family member was granted in the United States by the USPTO. This is evidence for the significant opportunity Nanoform has to generate valuable IP leveraging its platforms for nanoformulations and products. The cPEN TM formulation platform is utilized for nanoenzalutamide, nanoapalutamide, and nanoencorafenib, among other internal and ongoing customer projects Nanoform's AGM was held on April 15, 2025. 42 shareholders representing 58.9% of all outstanding shares and votes were represented at the meeting (for more information see section AGM decisions). In April, Nanoform won a new grant from the Gates Foundation to work on several of the foundation’s drug development projects. In April, our Bio R&D team achieved a 10x scale-up of our Biologics technology, by producing 2kg in one continuous run on our pilot GMP line. This supports our efforts to show the commercial value the technology can bring to the fast growing field of high-concentration subcutaneous injections of monoclonal antibodies (mAbs). In April we successfully concluded our GMP campaign of nanoenzalutamide. 100kg material was produced and shipped to Bluepharma, where hundreds of thousands of tablets are produced. This successful campaign has resulted in a validated process for nanoenzalutamide. This supports our upcoming regulatory filings. In May Nanoform signed a letter of intent to establish, in collaboration with two specialist healthcare investors, BRAFMed Ltd, a new company to progress the clinical development and outlicensing of Nanoencorafenib In June Takeda presented results related to their project with Nanoform's Biologics technology at the Drug Delivery Forum in Berlin. The presentation entitled “A Novel Nanoformed Presentation of AAT for the Treatment of Pulmonary Emphysema in AAT Deficient Patients,” shared results from the study, which investigated Nanoformed A1AT, a respirable dry powder for inhalation, as an alternative administration strategy for an AAT replacement therapy, based on a novel solidification platform from Nanoform. Inhaled A1AT could help achieving much higher A1AT levels in the epithelium lining fluid while offering a more patient centric formulation. In June at DDF in Berlin Nanoform presented the successful generation of nanotrastuzumab, a high concentration nanoformulation of trastuzumab, suitable for subcutaneous injection, enabling more than 400mg/ml dose in a single 2mL syringe, instead of intravenous injections. In June Nanoform announced that it together with its ONConcept® Consortium partners (Bluepharma, Helm, Welding) had started pivotal relative bioequivalence studies of Nanoenzalutamide. The purpose of the studies (fed/fasted, EU&US) is to achieve bioequivalence for a single nanoformed 160 mg tablet dose with four Xtandi® 40 mg film-coated tablets. In June Business Finland approved a EUR 5m R&D loan to support the clinical development of nanoapalutamide, The loan covers up to 50% of the costs associated with the clinical development program through to the pivotal bioequivalence study. The interest rate on the loan is three percentage points below the base interest rate, or at least one percent, and no collateral is required. The loan period is ten years. During the first five years only interest is paid. Significant events after 1-6/2025 In August Nanoform received the first preliminary results from the first arm of the pivotal clinical study of nanoenzalutamide, a nanocrystalline-enabled tablet formulation of enzalutamide developed using Nanoform’s proprietary CESS ® technology. Nanoenzalutamide is being developed in partnership with the ONConcept ® Consortium (Bluepharma, Helm, Welding). This read-out was from the first arm of the pivotal study, a single-dose, randomized, open-label, parallel, bioequivalence study of nanoenzalutamide 160 mg film-coated tablets and Xtandi® (enzalutamide) 4 x 40 mg film-coated tablets (Astellas Pharma Europe B.V.) in healthy male volunteers under fasting conditions. The results demonstrated that nanoenzalutamide in fasted study subjects showed matching plasma concentration (“AUC”) compared to the reference product, and slightly low peak plasma concentration (“Cmax”). Nanoform and the ONConcept ® consortium’s initial assessment is that the results are supportive for nanoenzalutamide to progress to the markets underpinned by an adjusted regulatory strategy. The ongoing clinical study continues with dosing under fed conditions as planned. Nanoform and ONConcept ® remain confident that the unique patient-centric crystalline one tablet formulation will offer an attractive product for partners and patients, with the opportunity to potentially launch prior to other generic products relying on the amorphous solid dispersion formulation that is patent protected until 2033. Nanoform does not currently expect there to be material changes to earlier volume- and commercial estimates provided in connection with Nanoform’s 1Q report. Company near-term business targets for 2025 To sign development and license/commercial supply agreements on several product kernels during 2025 First pivotal bioequivalence study with nanoformed medicine Increased number of non-GMP and GMP projects signed in 2025 vs 2024 Improved free cash flow in 2025 vs 2024 Company mid-term business targets 2030 To be announced during 2025 in conjunction with Capital Markets Day. Nanoform’s Q2 2025 report and management presentation can be found at: Nanoform online presentation and conference call August 21, 2025, at 3:00 p.m. Helsinki time / 2:00 p.m. Stockholm time: The company will hold an online presentation and conference call the same day at 3.00 p.m. Finnish time / 2.00 p.m. Swedish time. Nanoform will be represented by CEO Edward Hæggström, CFO Albert Hæggström, CCO Christian Jones and CDO/General Counsel Peter Hänninen. The presentation will be delivered in English. The presentation will be broadcasted live and participants may access the event via audiocast and teleconference through the following link: To participate in the event, attendees are required to register. To join the Q&A session, attendees must access the teleconference by dialing in. Upon registration, participants will receive a dial-in number, a conference ID, and a personal User ID to access the conference. Please note that questions can only be submitted through the teleconference line. For further information, please contact: Dr. Edward Hæggström, CEO +358 (0)29 370 0150 Henri von Haartman, Director of Investor Relations +46 (0)7686 650 11 About Nanoform Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services, from pre-clinical to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: DNB Carnegie Investment Bank AB, +46 (0)73 856 42 65, . For more information, please visit . Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform’s strategy, business plans and focus. The words “may”, “will”, “could”, “would”, “should”, “expect”, “plan”, “anticipate”, “intend”, believe”, “estimate”, “predict”, “project”, “potential”, “continue”, “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform’s business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks described in the Report of the Board of Directors and Financial Statements for the year ended December 31, 2024 as well as our other past disclosures. Nanoform cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Nanoform’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Attachments: Nanoform Q2 Interim Report 2025.pdf This email message was delivered to Cancel this subscription This news release was distributed by Company News System, nasdaq.com/european-market-activity/news/company-news"
198cb1d298e68b77,ALK,unknown,2025-08-21,2025-08-21T05:41:14+00:00,Six-month interim report (Q2) 2025 (unaudited),"August 21, 2025 1:31 AM EDT
Six-month interim report (Q2) 2025 (unaudited)
View this release →
Or 
click here
 to view all releases.
You are subscribed to ALK Investor Relations' email alerts.
To unsubscribe from all alerts, please 
click here
.
ALK
Bøge Allé 6-8  DK-2970, Hørsholm,  , Denmark
Service provided by Notified

",gmail,,1,1,Six-month interim report (Q2) 2025 (unaudited),"August 21, 2025 1:31 AM EDT Six-month interim report (Q2) 2025 (unaudited) View this release → Or click here to view all releases. You are subscribed to ALK Investor Relations' email alerts. To unsubscribe from all alerts, please click here . ALK Bøge Allé 6-8 DK-2970, Hørsholm, , Denmark Service provided by Notified"
198cebe9f0f08ca1,Qiiwi Games AB,unknown,2025-08-21,2025-08-21T22:31:19+00:00,Delårsrapport kvartal 2 2025,"





Delårsrapport kvartal 2 2025





































            Publicerad: 2025-08-21 08:30:00 CEST
        








Qiiwi Games AB - Pressmeddelande
Delårsrapport kvartal 2 2025


Andra kvartalet 1 april - 30 juni 2025




Omsättning 3 266 TSEK (5 413)


Rörelseresultat före avskrivningar (EBITDA) -1 761 TSEK (-1 976)


Rörelseresultat (EBIT) -2 706 TSEK (-2 966)


Resultat efter skatt -2 733 TSEK (-2 908)


Resultat per aktie uppgick före och efter utspädning till -0,30 SEK (-0,31)




Halvår (6 månader) januari - juni 2025




Omsättning 8 165 TSEK (11 473) 


Rörelseresultat före avskrivningar (EBITDA) -3 329 TSEK (-4 894) 


Rörelseresultat (EBIT) -5 245 TSEK (-6 872)


Resultat efter skatt -5 424 TSEK (-6 752) 


Resultat per aktie uppgick före och efter utspädning till -0,59 SEK (-0,73)




Väsentliga händelser under perioden




Strategisk omorganisation och kostnadsbesparingar




Bolaget meddelade den 2 juni 2025 att ledningen genomfört en översyn kring bolagets organisation med målsättningen att erhålla kostnadsbesparingar i den löpande operativa driften.   Kostnadsbesparingar och en omorganisation genomförs omdelbart där personalstyrkan minskas med 50%, det cypriotiska dotterbolaget avvecklas samt att AI blir en integrerad del i verksamhetens samtliga steg. Samtliga kostnadsbesparingar beräknas ge full effekt innan årets utgång.  Avvecklingen av det cypriotiska dotterbolaget innebär ingen initial resultat- eller kassaflödeseffekt för koncernen under det andra kvartalet. Däremot har moderbolagets andelar i dotterbolaget skrivits ned vilket påverkar moderbolagets resultat i perioden om 591 TSEK.




Väsentliga händelser efter periodens utgång




CFO lämnar sin befattning




Bolaget meddelade den 8 juli 2025 att CFO Martin Larsson har beslutat att lämna sin position för att ta sig an nya utmaningar utanför bolaget. Martin kommer att kvarstå i sin roll tills en efterträdare har utsetts för att säkra en god överlämning. En rekryteringsprocess har inletts.

	 


Storägare ökar sitt innehav till över 20%




Bolaget meddelade den 16 juli 2025 att bolagets storägare Özkan Egos innehav nu överstiger 20% av totalt antal aktier och röster i bolaget efter ett antal genomförda insynsköp under juni och juli. Özkan är även styrelseordförande och medgrundare till Qiiwi Games.




VD har ordet:


""
AI-muskler hjälper oss fortsätta tänka och bygga stort!
""


Under det andra kvartalet informerade vi om ytterligare optimeringar och kostnadsbesparingar i vår verksamhet. Detta då vi de senaste åren odlat ett AI-fokuserat tankesätt, något vi nu ser eskalerar mer och mer. Den effekt vi bedömmer kunna få genom AI framöver ledde till beslutet att minska personalstyrkan med totalt 50% samt helt avveckla vårt dotterbolag på Cypern.


Bedömningen är att dessa förändringar kommer ge en total minskad kostnadsbas per månad om ca 450 TSEK, troligtvis mer då ytterligare besparingar har identifierats under Q2 och Q3. Detta förstärker bolagets möjlighet att som ett första steg driva verksamheten mot ett break-even resultat på månadsbasis.


""Minskad omsättning men stabiliserad under Q2""


Under den rapporterade perioden når vi en omsättning på ca 3,3 MSEK jämfört med ca 5,4 MSEK under samma period föregående år. Minskningen härleds till minskade intäkter från speltitlar som presterade på högre nivå Q2 2024. Detta är bland annat Extreme Makeover: Home Edition samt Midsomer Murders, speltitlar som bolaget i dagsläget fokuserar mindre på.


Under det andra kvartalet och även in i det tredje har vi sett en positiv utveckling av intäkter månad - månad, vilket innebär en stabilisering och mindre ökning av Live Operations-portföljen. Vi genererar dock lägre intäkter jämfört med första kvartalet 2025, vilket beror på att merparten av det kvartalets intäkter generades under januari i samband med vår globala lansering av Backpacker® Go!.


Det är positivt att vi lyckats stabilisera och vända trenden av minskade intäkter under det andra kvartalet. Detta är drivet av förbättringar i avkastning på marknadsföring för Backpacker® Go! men även Wordington.



De tre största bidragsgivarna kopplat till periodens omsättning har varit:

 

1. Backpacker® Go! (44%)

2. Wordington (24%)

3. Extreme Makeover (9%)


Vi når ett något förbättrat EBITDA-resultat jämfört med samma period föregående år. Vid full effekt av våra kostnadsbesparingar mot senare delen av året förväntar vi oss att se ett förbättrat EBITDA-resultat kommande kvartal.


""Marknadsföring/UA""


En grundläggande del i den förbättrade avkastningen på investeringar i marknadsföring är användandet av AI i generering av annonsmaterial, något som gör att vi betydligt snabbare kan utvärdera nya annonskoncept. Med detta arbetssätt skall vi fortsätta utvärdera även andra speltitlar i portföljen för att se om vi kan nå nya insikter om tillväxtpotential för dessa.


Under den rapporterade perioden har vi totalt investerat ca 1,2 MSEK jämfört med ca 2,7 MSEK samma period föregående år, en minskning med ca 55%. Jämför vi mot Q1 2025, under Backpacker® Go! globala lansering, minskade investeringarna i marknadsföring med ca 48%.


Investeringar i marknadsföring är fluktuerande och beror på om vi har nya spel att lansera som befinner sig i en uppskalningsfas eller ej. Under den rapporterade perioden har vi inte haft några spel i den fasen utan fokuserat på att investera i marknadsföring där vi är trygga att nå vårt mål med 100% avkastning inom 180 dagar.


""New Games""


Inom New Games har vi under perioden utvärderat flera nya spelidéer och prototyper, framför allt har vi lagt fokus på att utvärdera Zen-tema i kombination med ordpussel. En avslappnande spelupplevelse som är populär där vi vill skapa oss egna insikter kring potential. I dagsläget är detta test i sin slutfas.


Vi har även fokuserat på att förenkla processen kring att testa nya spelidéer ytterligare genom att påbörja arbetet med att ta fram något vi kallar för “The Qiiwi Template”. Detta innebär att vi framöver kommer kunna testa nya spelidéer med ett betydligt bredare bibliotek av viktiga spelfunktioner redan från start, funktioner som är viktiga för att kunna avgöra ett spels långsiktiga kvarhållningsgrad/retention.


Vi har flera väldigt spännande spelidéer som skall realiseras och testas framöver där kombinationen av användandet av AI är högst på prioriteringslistan.


""Live Operations""


Under perioden har speltiteln Backpacker® Go! övergått i Live Operations-status vilket innebär att vi mer fokuserar på att stabilisera speltitelns lönsamhet än tillväxt. Under perioden har vi förbättrat funktionerna i spelet relaterat till lagspel och event. Spelet täcker just nu 112 städer och 18 så kallade “Stjärndestinationer” där spelare ges möjlighet att besöka specifika platser både på jorden men även i rymden med sitt lag.


Under perioden lanserade vi även en uppdatering till speltiteln MasterChef där vi med mindre arbetsinsatser ställt om spelet till ett mer rent match-3-spel likt Extreme Makeover: Home Edition. MasterChef är ett starkt varumärke som driver organiska nedladdningar från spelbutikerna. Målsättningen med denna uppdatering är att se om denna ändring vi genomfört kan leda till någon form av förbättring relaterat till kvarhållning/retention av spelare, vilket i så fall kan ge ökande intäkter inom Live Operations-portföljen.


""Qiiwi Games - Ett litet team stärkt av AI""


På Qiiwi Games strävar vi dagligen efter att maximera den effekten vi kan få genom att nyttja AI-tjänster inom vår arbetsprocess fullt ut. Detta innebär även hur vi kan bygga spel som i sin spelmekanik nyttjar AI för att till exempel skapa unika spelupplevelser och automatiskt utöka tillgängligt innehåll i våra spel. Här är till exempel AI-agenter som sköter stora delar av ett spels livscykel något vi tror mycket på. Denna utveckling är extremt spännande och lyckas vi väl här och kan ta snabbare steg än våra konkurrenter ser framtiden ljus ut. Föreställ er en organisation som skalar upp med fler AI-agenter, istället för fler anställda - till en bråkdel av kostnaden.


Vi bedömer att vi i dagsläget är på rätt väg mot att nå positivt kassaflöde när samtliga kostnadsbesparingar gett full effekt vilket sker mot slutet av året. Med de nu genomförda ytterligare optimeringarna i vår verksamhet och en stabil kassa kommer vi framöver arbeta hårdare än någonsin för att ta oss till nya betydligt högre nivåer!


Erik Dale Rundberg, VD, Qiiwi Games AB


För mer information se bifogad kvartalsrapport samt anslut till bolagets presentation av rapporten för det andra kvartalet samt Q/A-Frågestund som hålls idag 10:00 via Zoom. För att ansluta till mötet följer man nedan länk:


https://zoom.us/j/97416918489


För ytterligare information:


Erik Dale Rundberg, VD, Qiiwi Games AB

Telefon: +46709260697

E-mail: 
erik@qiiwi.com


Denna information är sådan information som Qiiwi Games AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 21
 augusti 
2025
 kl. 08:30 CEST.


Certified Adviser:


Bergs Securities AB

Telefon: +46 73 949 6250


ca@bergssecurities.se


Om Qiiwi Games:


Qiiwi Games är en utvecklare av spel till mobila plattformar som iOS och Android. Bolagets nuvarande verksamhet startade 2012 och bolaget har sitt huvudkontor och spelstudio i Alingsås (Sverige). Qiiwi fokuserar på att utveckla mobilspel riktade mot “Casual Gamers"". Bolagets slogan är “Where Minds Thrive"".




















Bifogade filer:


08213679.pdf













        This email message was delivered to rs.newsfeed.123@gmail.com
        





			Avsluta denna prenumeration
		















                            This news release was distributed by Company News System, 
nasdaq.com/european-market-activity/news/company-news



















",gmail,,1,1,Delårsrapport kvartal 2 2025,"Delårsrapport kvartal 2 2025 Publicerad: 2025-08-21 08:30:00 CEST Qiiwi Games AB - Pressmeddelande Delårsrapport kvartal 2 2025 Andra kvartalet 1 april - 30 juni 2025 Omsättning 3 266 TSEK (5 413) Rörelseresultat före avskrivningar (EBITDA) -1 761 TSEK (-1 976) Rörelseresultat (EBIT) -2 706 TSEK (-2 966) Resultat efter skatt -2 733 TSEK (-2 908) Resultat per aktie uppgick före och efter utspädning till -0,30 SEK (-0,31) Halvår (6 månader) januari - juni 2025 Omsättning 8 165 TSEK (11 473) Rörelseresultat före avskrivningar (EBITDA) -3 329 TSEK (-4 894) Rörelseresultat (EBIT) -5 245 TSEK (-6 872) Resultat efter skatt -5 424 TSEK (-6 752) Resultat per aktie uppgick före och efter utspädning till -0,59 SEK (-0,73) Väsentliga händelser under perioden Strategisk omorganisation och kostnadsbesparingar Bolaget meddelade den 2 juni 2025 att ledningen genomfört en översyn kring bolagets organisation med målsättningen att erhålla kostnadsbesparingar i den löpande operativa driften. Kostnadsbesparingar och en omorganisation genomförs omdelbart där personalstyrkan minskas med 50%, det cypriotiska dotterbolaget avvecklas samt att AI blir en integrerad del i verksamhetens samtliga steg. Samtliga kostnadsbesparingar beräknas ge full effekt innan årets utgång. Avvecklingen av det cypriotiska dotterbolaget innebär ingen initial resultat- eller kassaflödeseffekt för koncernen under det andra kvartalet. Däremot har moderbolagets andelar i dotterbolaget skrivits ned vilket påverkar moderbolagets resultat i perioden om 591 TSEK. Väsentliga händelser efter periodens utgång CFO lämnar sin befattning Bolaget meddelade den 8 juli 2025 att CFO Martin Larsson har beslutat att lämna sin position för att ta sig an nya utmaningar utanför bolaget. Martin kommer att kvarstå i sin roll tills en efterträdare har utsetts för att säkra en god överlämning. En rekryteringsprocess har inletts. Storägare ökar sitt innehav till över 20% Bolaget meddelade den 16 juli 2025 att bolagets storägare Özkan Egos innehav nu överstiger 20% av totalt antal aktier och röster i bolaget efter ett antal genomförda insynsköp under juni och juli. Özkan är även styrelseordförande och medgrundare till Qiiwi Games. VD har ordet: "" AI-muskler hjälper oss fortsätta tänka och bygga stort! "" Under det andra kvartalet informerade vi om ytterligare optimeringar och kostnadsbesparingar i vår verksamhet. Detta då vi de senaste åren odlat ett AI-fokuserat tankesätt, något vi nu ser eskalerar mer och mer. Den effekt vi bedömmer kunna få genom AI framöver ledde till beslutet att minska personalstyrkan med totalt 50% samt helt avveckla vårt dotterbolag på Cypern. Bedömningen är att dessa förändringar kommer ge en total minskad kostnadsbas per månad om ca 450 TSEK, troligtvis mer då ytterligare besparingar har identifierats under Q2 och Q3. Detta förstärker bolagets möjlighet att som ett första steg driva verksamheten mot ett break-even resultat på månadsbasis. ""Minskad omsättning men stabiliserad under Q2"" Under den rapporterade perioden når vi en omsättning på ca 3,3 MSEK jämfört med ca 5,4 MSEK under samma period föregående år. Minskningen härleds till minskade intäkter från speltitlar som presterade på högre nivå Q2 2024. Detta är bland annat Extreme Makeover: Home Edition samt Midsomer Murders, speltitlar som bolaget i dagsläget fokuserar mindre på. Under det andra kvartalet och även in i det tredje har vi sett en positiv utveckling av intäkter månad - månad, vilket innebär en stabilisering och mindre ökning av Live Operations-portföljen. Vi genererar dock lägre intäkter jämfört med första kvartalet 2025, vilket beror på att merparten av det kvartalets intäkter generades under januari i samband med vår globala lansering av Backpacker® Go!. Det är positivt att vi lyckats stabilisera och vända trenden av minskade intäkter under det andra kvartalet. Detta är drivet av förbättringar i avkastning på marknadsföring för Backpacker® Go! men även Wordington. De tre största bidragsgivarna kopplat till periodens omsättning har varit: 1. Backpacker® Go! (44%) 2. Wordington (24%) 3. Extreme Makeover (9%) Vi når ett något förbättrat EBITDA-resultat jämfört med samma period föregående år. Vid full effekt av våra kostnadsbesparingar mot senare delen av året förväntar vi oss att se ett förbättrat EBITDA-resultat kommande kvartal. ""Marknadsföring/UA"" En grundläggande del i den förbättrade avkastningen på investeringar i marknadsföring är användandet av AI i generering av annonsmaterial, något som gör att vi betydligt snabbare kan utvärdera nya annonskoncept. Med detta arbetssätt skall vi fortsätta utvärdera även andra speltitlar i portföljen för att se om vi kan nå nya insikter om tillväxtpotential för dessa. Under den rapporterade perioden har vi totalt investerat ca 1,2 MSEK jämfört med ca 2,7 MSEK samma period föregående år, en minskning med ca 55%. Jämför vi mot Q1 2025, under Backpacker® Go! globala lansering, minskade investeringarna i marknadsföring med ca 48%. Investeringar i marknadsföring är fluktuerande och beror på om vi har nya spel att lansera som befinner sig i en uppskalningsfas eller ej. Under den rapporterade perioden har vi inte haft några spel i den fasen utan fokuserat på att investera i marknadsföring där vi är trygga att nå vårt mål med 100% avkastning inom 180 dagar. ""New Games"" Inom New Games har vi under perioden utvärderat flera nya spelidéer och prototyper, framför allt har vi lagt fokus på att utvärdera Zen-tema i kombination med ordpussel. En avslappnande spelupplevelse som är populär där vi vill skapa oss egna insikter kring potential. I dagsläget är detta test i sin slutfas. Vi har även fokuserat på att förenkla processen kring att testa nya spelidéer ytterligare genom att påbörja arbetet med att ta fram något vi kallar för “The Qiiwi Template”. Detta innebär att vi framöver kommer kunna testa nya spelidéer med ett betydligt bredare bibliotek av viktiga spelfunktioner redan från start, funktioner som är viktiga för att kunna avgöra ett spels långsiktiga kvarhållningsgrad/retention. Vi har flera väldigt spännande spelidéer som skall realiseras och testas framöver där kombinationen av användandet av AI är högst på prioriteringslistan. ""Live Operations"" Under perioden har speltiteln Backpacker® Go! övergått i Live Operations-status vilket innebär att vi mer fokuserar på att stabilisera speltitelns lönsamhet än tillväxt. Under perioden har vi förbättrat funktionerna i spelet relaterat till lagspel och event. Spelet täcker just nu 112 städer och 18 så kallade “Stjärndestinationer” där spelare ges möjlighet att besöka specifika platser både på jorden men även i rymden med sitt lag. Under perioden lanserade vi även en uppdatering till speltiteln MasterChef där vi med mindre arbetsinsatser ställt om spelet till ett mer rent match-3-spel likt Extreme Makeover: Home Edition. MasterChef är ett starkt varumärke som driver organiska nedladdningar från spelbutikerna. Målsättningen med denna uppdatering är att se om denna ändring vi genomfört kan leda till någon form av förbättring relaterat till kvarhållning/retention av spelare, vilket i så fall kan ge ökande intäkter inom Live Operations-portföljen. ""Qiiwi Games - Ett litet team stärkt av AI"" På Qiiwi Games strävar vi dagligen efter att maximera den effekten vi kan få genom att nyttja AI-tjänster inom vår arbetsprocess fullt ut. Detta innebär även hur vi kan bygga spel som i sin spelmekanik nyttjar AI för att till exempel skapa unika spelupplevelser och automatiskt utöka tillgängligt innehåll i våra spel. Här är till exempel AI-agenter som sköter stora delar av ett spels livscykel något vi tror mycket på. Denna utveckling är extremt spännande och lyckas vi väl här och kan ta snabbare steg än våra konkurrenter ser framtiden ljus ut. Föreställ er en organisation som skalar upp med fler AI-agenter, istället för fler anställda - till en bråkdel av kostnaden. Vi bedömer att vi i dagsläget är på rätt väg mot att nå positivt kassaflöde när samtliga kostnadsbesparingar gett full effekt vilket sker mot slutet av året. Med de nu genomförda ytterligare optimeringarna i vår verksamhet och en stabil kassa kommer vi framöver arbeta hårdare än någonsin för att ta oss till nya betydligt högre nivåer! Erik Dale Rundberg, VD, Qiiwi Games AB För mer information se bifogad kvartalsrapport samt anslut till bolagets presentation av rapporten för det andra kvartalet samt Q/A-Frågestund som hålls idag 10:00 via Zoom. För att ansluta till mötet följer man nedan länk: För ytterligare information: Erik Dale Rundberg, VD, Qiiwi Games AB Telefon: +46709260697 E-mail: Denna information är sådan information som Qiiwi Games AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 21 augusti 2025 kl. 08:30 CEST. Certified Adviser: Bergs Securities AB Telefon: +46 73 949 6250 Om Qiiwi Games: Qiiwi Games är en utvecklare av spel till mobila plattformar som iOS och Android. Bolagets nuvarande verksamhet startade 2012 och bolaget har sitt huvudkontor och spelstudio i Alingsås (Sverige). Qiiwi fokuserar på att utveckla mobilspel riktade mot “Casual Gamers"". Bolagets slogan är “Where Minds Thrive"". Bifogade filer: 08213679.pdf This email message was delivered to Avsluta denna prenumeration This news release was distributed by Company News System, nasdaq.com/european-market-activity/news/company-news"
